Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes
Blockade of angiotensin type 1 receptors slows the progression of nephropathy. This effect is independent of the reduction in blood pressure. Diabetes mellitus is increasing in prevalence worldwide and is currently estimated to affect more than 6.5 percent of the population of the United States. 1 D...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2001-09, Vol.345 (12), p.851-860 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 860 |
|---|---|
| container_issue | 12 |
| container_start_page | 851 |
| container_title | The New England journal of medicine |
| container_volume | 345 |
| creator | Lewis, Edmund J Lewis, Julia B Hunsicker, Lawrence G Clarke, William R Berl, Tomas Pohl, Marc A Ritz, Eberhard Atkins, Robert C Rohde, Richard Raz, Itamar |
| description | Blockade of angiotensin type 1 receptors slows the progression of nephropathy. This effect is independent of the reduction in blood pressure.
Diabetes mellitus is increasing in prevalence worldwide and is currently estimated to affect more than 6.5 percent of the population of the United States.
1
Diabetes is the most common cause of end-stage renal disease in this country, accounting for 40 percent of cases.
2
Although the inhibition of the effects of angiotensin II has a beneficial effect in patients with nephropathy caused by type 1 diabetes,
3
no published study with definitive renal outcomes has addressed the issue of renoprotection in patients with type 2 diabetes — a population that differs substantially from patients with type 1 diabetes in terms of demographic . . . |
| doi_str_mv | 10.1056/NEJMoa011303 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_223947907</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>81554035</sourcerecordid><originalsourceid>FETCH-LOGICAL-c543t-b0da64b20d507d5c74538e990ed2d31a24ffb7d369175c8a0e64f88453ba55ab3</originalsourceid><addsrcrecordid>eNpt0U1PGzEQBmCrKoLwceu5sqpy64K9tvfjiCBtQRRQlJ5Xs7vjxFHW3toOKOLP1yiR6KG-2LIfzWheE_KJswvOVHH5ML375YBxLpj4QCZcCZFJyYqPZMJYXmWyrMUROQ5hxdLisj4kR5yrQileTsjrDK0bvYvYRfOMdKp1OlGnaVwivbILk55sMDabYYdjdD5dRlg4a0Kkt77FAD6CpcbSJ4gGbQz0xcQlfcBx6d0IcbmlNxuk0dH5dkSa0xsDLUYMp-RAwzrg2X4_Ib-_T-fXP7P7xx-311f3WaekiFnLeihkm7NesbJXXSmVqLCuGfZ5LzjkUuu27EVR81J1FTAspK6qpFpQClpxQr7s6qY5_2wwxGblNt6mlk2eizoFxMqEvu1Q510IHnUzejOA3zacNW9BN_8Gnfjnfc1NO2D_jvfJJnC-BxA6WGsPtjPh3aUfqph4c193bhhCY3E1_L_fX3-IkZY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223947907</pqid></control><display><type>article</type><title>Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>New England Journal of Medicine</source><creator>Lewis, Edmund J ; Lewis, Julia B ; Hunsicker, Lawrence G ; Clarke, William R ; Berl, Tomas ; Pohl, Marc A ; Ritz, Eberhard ; Atkins, Robert C ; Rohde, Richard ; Raz, Itamar</creator><creatorcontrib>Lewis, Edmund J ; Lewis, Julia B ; Hunsicker, Lawrence G ; Clarke, William R ; Berl, Tomas ; Pohl, Marc A ; Ritz, Eberhard ; Atkins, Robert C ; Rohde, Richard ; Raz, Itamar ; Collaborative Study Group</creatorcontrib><description>Blockade of angiotensin type 1 receptors slows the progression of nephropathy. This effect is independent of the reduction in blood pressure.
Diabetes mellitus is increasing in prevalence worldwide and is currently estimated to affect more than 6.5 percent of the population of the United States.
1
Diabetes is the most common cause of end-stage renal disease in this country, accounting for 40 percent of cases.
2
Although the inhibition of the effects of angiotensin II has a beneficial effect in patients with nephropathy caused by type 1 diabetes,
3
no published study with definitive renal outcomes has addressed the issue of renoprotection in patients with type 2 diabetes — a population that differs substantially from patients with type 1 diabetes in terms of demographic . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa011303</identifier><identifier>PMID: 11565517</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Boston, MA: Massachusetts Medical Society</publisher><subject>Adult ; Aged ; Amlodipine - adverse effects ; Amlodipine - therapeutic use ; Angiotensin Receptor Antagonists ; Antihypertensive Agents - adverse effects ; Antihypertensive Agents - therapeutic use ; Biological and medical sciences ; Biphenyl Compounds - adverse effects ; Biphenyl Compounds - therapeutic use ; Calcium Channel Blockers - therapeutic use ; Committees ; Creatinine - blood ; Diabetes ; Diabetes Mellitus, Type 2 - complications ; Diabetic Nephropathies - complications ; Diabetic Nephropathies - drug therapy ; Double-Blind Method ; Female ; Humans ; Hypertension ; Hypertension - complications ; Hypertension - drug therapy ; Kidney Failure, Chronic - prevention & control ; Male ; Medical sciences ; Middle Aged ; Mortality ; Pharmacology. Drug treatments ; Proportional Hazards Models ; Tetrazoles - adverse effects ; Tetrazoles - therapeutic use ; Urinary system</subject><ispartof>The New England journal of medicine, 2001-09, Vol.345 (12), p.851-860</ispartof><rights>Copyright © 2001 Massachusetts Medical Society. All rights reserved.</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c543t-b0da64b20d507d5c74538e990ed2d31a24ffb7d369175c8a0e64f88453ba55ab3</citedby><cites>FETCH-LOGICAL-c543t-b0da64b20d507d5c74538e990ed2d31a24ffb7d369175c8a0e64f88453ba55ab3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa011303$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMoa011303$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14068037$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11565517$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lewis, Edmund J</creatorcontrib><creatorcontrib>Lewis, Julia B</creatorcontrib><creatorcontrib>Hunsicker, Lawrence G</creatorcontrib><creatorcontrib>Clarke, William R</creatorcontrib><creatorcontrib>Berl, Tomas</creatorcontrib><creatorcontrib>Pohl, Marc A</creatorcontrib><creatorcontrib>Ritz, Eberhard</creatorcontrib><creatorcontrib>Atkins, Robert C</creatorcontrib><creatorcontrib>Rohde, Richard</creatorcontrib><creatorcontrib>Raz, Itamar</creatorcontrib><creatorcontrib>Collaborative Study Group</creatorcontrib><title>Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Blockade of angiotensin type 1 receptors slows the progression of nephropathy. This effect is independent of the reduction in blood pressure.
Diabetes mellitus is increasing in prevalence worldwide and is currently estimated to affect more than 6.5 percent of the population of the United States.
1
Diabetes is the most common cause of end-stage renal disease in this country, accounting for 40 percent of cases.
2
Although the inhibition of the effects of angiotensin II has a beneficial effect in patients with nephropathy caused by type 1 diabetes,
3
no published study with definitive renal outcomes has addressed the issue of renoprotection in patients with type 2 diabetes — a population that differs substantially from patients with type 1 diabetes in terms of demographic . . .</description><subject>Adult</subject><subject>Aged</subject><subject>Amlodipine - adverse effects</subject><subject>Amlodipine - therapeutic use</subject><subject>Angiotensin Receptor Antagonists</subject><subject>Antihypertensive Agents - adverse effects</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Biphenyl Compounds - adverse effects</subject><subject>Biphenyl Compounds - therapeutic use</subject><subject>Calcium Channel Blockers - therapeutic use</subject><subject>Committees</subject><subject>Creatinine - blood</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetic Nephropathies - complications</subject><subject>Diabetic Nephropathies - drug therapy</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Hypertension - complications</subject><subject>Hypertension - drug therapy</subject><subject>Kidney Failure, Chronic - prevention & control</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Pharmacology. Drug treatments</subject><subject>Proportional Hazards Models</subject><subject>Tetrazoles - adverse effects</subject><subject>Tetrazoles - therapeutic use</subject><subject>Urinary system</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0U1PGzEQBmCrKoLwceu5sqpy64K9tvfjiCBtQRRQlJ5Xs7vjxFHW3toOKOLP1yiR6KG-2LIfzWheE_KJswvOVHH5ML375YBxLpj4QCZcCZFJyYqPZMJYXmWyrMUROQ5hxdLisj4kR5yrQileTsjrDK0bvYvYRfOMdKp1OlGnaVwivbILk55sMDabYYdjdD5dRlg4a0Kkt77FAD6CpcbSJ4gGbQz0xcQlfcBx6d0IcbmlNxuk0dH5dkSa0xsDLUYMp-RAwzrg2X4_Ib-_T-fXP7P7xx-311f3WaekiFnLeihkm7NesbJXXSmVqLCuGfZ5LzjkUuu27EVR81J1FTAspK6qpFpQClpxQr7s6qY5_2wwxGblNt6mlk2eizoFxMqEvu1Q510IHnUzejOA3zacNW9BN_8Gnfjnfc1NO2D_jvfJJnC-BxA6WGsPtjPh3aUfqph4c193bhhCY3E1_L_fX3-IkZY</recordid><startdate>20010920</startdate><enddate>20010920</enddate><creator>Lewis, Edmund J</creator><creator>Lewis, Julia B</creator><creator>Hunsicker, Lawrence G</creator><creator>Clarke, William R</creator><creator>Berl, Tomas</creator><creator>Pohl, Marc A</creator><creator>Ritz, Eberhard</creator><creator>Atkins, Robert C</creator><creator>Rohde, Richard</creator><creator>Raz, Itamar</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20010920</creationdate><title>Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes</title><author>Lewis, Edmund J ; Lewis, Julia B ; Hunsicker, Lawrence G ; Clarke, William R ; Berl, Tomas ; Pohl, Marc A ; Ritz, Eberhard ; Atkins, Robert C ; Rohde, Richard ; Raz, Itamar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c543t-b0da64b20d507d5c74538e990ed2d31a24ffb7d369175c8a0e64f88453ba55ab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Amlodipine - adverse effects</topic><topic>Amlodipine - therapeutic use</topic><topic>Angiotensin Receptor Antagonists</topic><topic>Antihypertensive Agents - adverse effects</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Biphenyl Compounds - adverse effects</topic><topic>Biphenyl Compounds - therapeutic use</topic><topic>Calcium Channel Blockers - therapeutic use</topic><topic>Committees</topic><topic>Creatinine - blood</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetic Nephropathies - complications</topic><topic>Diabetic Nephropathies - drug therapy</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Hypertension - complications</topic><topic>Hypertension - drug therapy</topic><topic>Kidney Failure, Chronic - prevention & control</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Pharmacology. Drug treatments</topic><topic>Proportional Hazards Models</topic><topic>Tetrazoles - adverse effects</topic><topic>Tetrazoles - therapeutic use</topic><topic>Urinary system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lewis, Edmund J</creatorcontrib><creatorcontrib>Lewis, Julia B</creatorcontrib><creatorcontrib>Hunsicker, Lawrence G</creatorcontrib><creatorcontrib>Clarke, William R</creatorcontrib><creatorcontrib>Berl, Tomas</creatorcontrib><creatorcontrib>Pohl, Marc A</creatorcontrib><creatorcontrib>Ritz, Eberhard</creatorcontrib><creatorcontrib>Atkins, Robert C</creatorcontrib><creatorcontrib>Rohde, Richard</creatorcontrib><creatorcontrib>Raz, Itamar</creatorcontrib><creatorcontrib>Collaborative Study Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lewis, Edmund J</au><au>Lewis, Julia B</au><au>Hunsicker, Lawrence G</au><au>Clarke, William R</au><au>Berl, Tomas</au><au>Pohl, Marc A</au><au>Ritz, Eberhard</au><au>Atkins, Robert C</au><au>Rohde, Richard</au><au>Raz, Itamar</au><aucorp>Collaborative Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2001-09-20</date><risdate>2001</risdate><volume>345</volume><issue>12</issue><spage>851</spage><epage>860</epage><pages>851-860</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>Blockade of angiotensin type 1 receptors slows the progression of nephropathy. This effect is independent of the reduction in blood pressure.
Diabetes mellitus is increasing in prevalence worldwide and is currently estimated to affect more than 6.5 percent of the population of the United States.
1
Diabetes is the most common cause of end-stage renal disease in this country, accounting for 40 percent of cases.
2
Although the inhibition of the effects of angiotensin II has a beneficial effect in patients with nephropathy caused by type 1 diabetes,
3
no published study with definitive renal outcomes has addressed the issue of renoprotection in patients with type 2 diabetes — a population that differs substantially from patients with type 1 diabetes in terms of demographic . . .</abstract><cop>Boston, MA</cop><pub>Massachusetts Medical Society</pub><pmid>11565517</pmid><doi>10.1056/NEJMoa011303</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2001-09, Vol.345 (12), p.851-860 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_journals_223947907 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; New England Journal of Medicine |
| subjects | Adult Aged Amlodipine - adverse effects Amlodipine - therapeutic use Angiotensin Receptor Antagonists Antihypertensive Agents - adverse effects Antihypertensive Agents - therapeutic use Biological and medical sciences Biphenyl Compounds - adverse effects Biphenyl Compounds - therapeutic use Calcium Channel Blockers - therapeutic use Committees Creatinine - blood Diabetes Diabetes Mellitus, Type 2 - complications Diabetic Nephropathies - complications Diabetic Nephropathies - drug therapy Double-Blind Method Female Humans Hypertension Hypertension - complications Hypertension - drug therapy Kidney Failure, Chronic - prevention & control Male Medical sciences Middle Aged Mortality Pharmacology. Drug treatments Proportional Hazards Models Tetrazoles - adverse effects Tetrazoles - therapeutic use Urinary system |
| title | Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T04%3A47%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Renoprotective%20Effect%20of%20the%20Angiotensin-Receptor%20Antagonist%20Irbesartan%20in%20Patients%20with%20Nephropathy%20Due%20to%20Type%202%20Diabetes&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Lewis,%20Edmund%20J&rft.aucorp=Collaborative%20Study%20Group&rft.date=2001-09-20&rft.volume=345&rft.issue=12&rft.spage=851&rft.epage=860&rft.pages=851-860&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJMoa011303&rft_dat=%3Cproquest_cross%3E81554035%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223947907&rft_id=info:pmid/11565517&rfr_iscdi=true |